MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced positive updated data from its THIO-101 ...

One milliliter of culture was added to 100 mL of LB with 30 μg/mL kanamycin monosulfate and incubated at 37°C and 160 r/min until the OD 600 reached 0.4–0.6. Expression was induced with 0.1 mM ...